Overview

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase II, single-Arm, prospective study of neoadjuvant Icotinib with chemotherapy for the treatment of patients with epidermal growth factor receptor mutation positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer

Phase:

Phase 2

Details

Lead Sponsor:

Beijing Cancer Hospital

Treatments:

Carboplatin
Pemetrexed